glioblastoma malignant primary brain tumor
Conditions
Interventions
None listed
Sponsors
European Organisation for Research in Treatment of Cancer (EORTC)
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients: - Age > 18 years at diagnosis - Histopathological diagnosis of glioblastoma (reference histology available) - Survival >5 years from diagnosis - Availability of tumor tissue from initial glioblastoma diagnosis (FFPE or fresh-frozen) to validate the diagnosis centrally - Signed consent form (living patients) or no documentation of previous objection of the patient to any of these purposes, and the meaningful aim of the data / material collection and use to research (deceased patients), and a notification to an ethics committee for the re-use of these data and samples, and any other national requirements Caregivers: - Optional stool collection for in-living caregivers: * > 18 years old * In-living caregiver (spouse, in-living family members, in-living housekeeper) * Exposed to same environment and share meals at a regular basis with patient * The patient that the caregiver is taking care of, has provided or will provide a stool sample * The patient has consented to contact the caregiver for the project. - Optional caregiver questionnaires for in-living caregivers or close caregivers: * > 18 years old * The patient has consented to contact the caregiver for the project * In-living caregiver (spouse, in-living family members, in-living housekeeper) or close caregiver (not in-living family member, not in-living housekeeper)
Exclusion criteria
Exclusion criteria: Optional stool collection for in-living caregivers - Cancer in the past 3 years (carcinomas in situ in the past 3 years are allowed) - IBD (Inflammatory Bowel Disease) e.g. Crohn, Colitis Ulcerosa - Medications for gastro-intestinal motility within the last 3 months - Systemic Antibiotics within the last month - Systemic corticosteroids - Previous extensive gastro-intestinal surgery - Use of probiotics containing live bacteria or yeast - Consent of another caregiver of the same patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) patient characteristics and (host)-related factors 2) identification of molecular tumor characteristics 3) therapy-related parameters including (neuro)toxicity 4) immunological studies | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
Netherlands
Outcome results
None listed